BridgeBio Pharma, Inc. (BBIO) stock
BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$77.36−0.94 (-1.20%)
Close on Nov 16, 2026Market cap $15.07BP/E –Yield –
BridgeBio Pharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
BridgeBio Pharma's operating cash flow for the twelve months ending Sep 30, 2026 was -$368.97M. For fiscal 2025 it was -$445.91M. The highest annual figure on record is -$40.49M in fiscal 2017.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$445.91M | – |
| FY2024 | Dec 31, 2024 | -$520.73M | – |
| FY2023 | Dec 31, 2023 | -$527.72M | – |
| FY2022 | Dec 31, 2022 | -$419.49M | – |
| FY2021 | Dec 31, 2021 | -$497.93M | – |
| FY2020 | Dec 31, 2020 | -$399.71M | – |
| FY2019 | Dec 31, 2019 | -$253.59M | – |
| FY2018 | Dec 31, 2018 | -$136.64M | – |
| FY2017 | Dec 31, 2017 | -$40.49M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$44.17M | – |
| Q2 FY2026 | Jun 30, 2026 | -$71.10M | – |
| Q1 FY2026 | Mar 31, 2026 | -$197.28M | – |
| Q4 FY2025 | Dec 31, 2025 | -$56.42M | – |
| Q3 FY2025 | Sep 30, 2025 | -$109.57M | – |
| Q2 FY2025 | Jun 30, 2025 | -$80.68M | -208.0% |
| Q1 FY2025 | Mar 31, 2025 | -$199.24M | – |
| Q4 FY2024 | Dec 31, 2024 | -$195.33M | – |
| Q3 FY2024 | Sep 30, 2024 | -$180.57M | – |
| Q2 FY2024 | Jun 30, 2024 | $74.70M | – |
| Q1 FY2024 | Mar 31, 2024 | -$219.54M | – |
| Q4 FY2023 | Dec 31, 2023 | -$124.82M | – |
| Q3 FY2023 | Sep 30, 2023 | -$145.23M | – |
| Q2 FY2023 | Jun 30, 2023 | -$113.35M | – |
| Q1 FY2023 | Mar 31, 2023 | -$144.32M | – |
| Q4 FY2022 | Dec 31, 2022 | -$93.24M | – |
| Q3 FY2022 | Sep 30, 2022 | -$135.16M | – |
| Q2 FY2022 | Jun 30, 2022 | -$30.45M | – |
| Q1 FY2022 | Mar 31, 2022 | -$160.64M | – |
| Q4 FY2021 | Dec 31, 2021 | -$133.90M | – |
| Q3 FY2021 | Sep 30, 2021 | -$121.56M | – |
| Q2 FY2021 | Jun 30, 2021 | -$91.71M | – |
| Q1 FY2021 | Mar 31, 2021 | -$150.77M | – |
| Q4 FY2020 | Dec 31, 2020 | -$96.26M | – |
| Q3 FY2020 | Sep 30, 2020 | -$131.68M | – |
| Q2 FY2020 | Jun 30, 2020 | -$87.85M | – |
| Q1 FY2020 | Mar 31, 2020 | -$83.92M | – |
| Q4 FY2019 | Dec 31, 2019 | -$76.20M | – |
| Q3 FY2019 | Sep 30, 2019 | -$50.00M | – |
| Q2 FY2019 | Jun 30, 2019 | -$68.25M | – |
| Q1 FY2019 | Mar 31, 2019 | -$59.14M | – |
| Q4 FY2018 | Dec 31, 2018 | -$46.41M | – |
See a number that looks wrong?